Dynavax Technologies Corporation  

(Public, NASDAQ:DVAX)   Watch this stock  
Find more results for DVAX
9.60
+0.05 (0.52%)
Jul 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.45 - 9.85
52 week 3.20 - 17.50
Open 9.65
Vol / Avg. 0.00/1.77M
Mkt cap 528.33M
P/E     -
Div/yield     -
EPS -2.82
Shares 54.75M
Beta 1.40
Inst. own 59%
Aug 3, 2017
Q2 2017 Dynavax Technologies Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 31, 2017
Dynavax Technologies Corp Extraordinary Shareholders Meeting - 12:00PM EDT - Add to calendar
May 31, 2017
Dynavax Technologies Corp Annual Shareholders Meeting
May 8, 2017
Q1 2017 Dynavax Technologies Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -17085.81% -1018.24%
Operating margin -17197.30% -1002.51%
EBITD margin - -959.42%
Return on average assets -92.28% -68.92%
Return on average equity -108.71% -81.40%
Employees 251 -
CDP Score - -

Address

2929 7th St Ste 100
BERKELEY, CA 94710-2753
United States - Map
+1-510-8485100 (Phone)
+1-510-8481327 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Officers and directors

Arnold L. Oronsky Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Eddie Gray Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Michael S. Ostrach Principal Financial Officer, Vice President, General Counsel, Chief Business Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Coffman Ph.D. Senior Vice President, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
David F. Novack Senior Vice President - Operations and Quality
Age: 53
Bio & Compensation  - Reuters
David Louis Johnson Chief Accounting Officer, Vice President
Age: 57
Bio & Compensation  - Reuters
Robert Janssen M.D. Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 59
Bio & Compensation  - Reuters
Natale S. Ricciardi Director
Age: 68
Bio & Compensation  - Reuters
Francis R. Cano Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters